Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

ResMed Continues To Build Digital-Medicine Business With $225M Acquisition Of Propeller Health

Executive Summary

Propeller Health bills itself as a digital respiratory therapeutics company, providing a mobile platform that communicates with sensors on patients' inhaler devices to help them manage chronic obstructive pulmonary disease and asthma. This the second major acquisition ResMed has announced in the last month.

You may also be interested in...



Exec Chat: ResMed's CEO Mick Farrell Outlines 2025 Strategy For 250 Million Users

ResMed's CEO Mick Farrell outlined the company's 2025 strategy: double-digit growth, drive up its user base to 250 million people and becoming the leading digital health company in both sleep apnea and chronic obstructive pulmonary (COPD) disease. Medtech Insight sat down with Farrell at ResMed's San Diego headquarters to learn more.

Results Recap: Five-year CoreValve Results Support Durability Of TAVR

Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition, covering the week of Nov. 23 - Nov. 29, includes five-year data from the CoreValve US Pivotal Trial, the longest-term follow-up data from a randomized trial of Medtronic's CoreValve TAVR system, show it remains durable with low rates of severe hemodynamic structural valve deterioration compared to surgical valves. Also, results of a 2,800-patient study sponsored by Propeller Health, shows use of rescue-inhaler increased significantly along with increases in daily fine particulate matter exposure.

ResMed Buys MatrixCare For $750M To Add Skilled-Nursing And Senior-Living Software

ResMed, one of the dominant players in the sleep-disorder market, has signed a definitive deal to buy Minnesota-based MatrixCare to augment its expanding software-as-a-service business with MatrixCare's electronic health record platform for long-term care settings.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT124325

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel